PharMerica at multi-year high after strong Q3 report

PharMerica (PMC +25.7%) soars after smashing the estimate of analysts with its Q3 report.

Results were boosted by cost-containment measures and an industry-leading generic dispensing rate of 83.3%.

The company boosted its forecast for full-year EPS to $1.71-$1.76, up from a prior range of $1.55-$1.60 and above the consensus estimate of analysts of $1.60.(PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs